$FLGT News

Last published 6d ago

6d agoFLGTFulgent Genetics 3Q2026 conference call and webcast - FULGENT GENETICS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the Fulton Genetics Q3 2026 conference call and webcast call. At this time, all lines are in listen-only mode, and following the presentation, we will conduct a questi
6d agoFLGTFulgent Genetics 3Q2026 conference call and webcast - FULGENT GENETICS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the Fulton Genetics Q3 2026 conference call and webcast call. At this time, all lines are in listen-only mode, and following the presentation, we will conduct a questi
6d agoFLGTFulgent Genetics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
3w agoFLGTFulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced
3mo agoFLGTFulgent Reports Second Quarter 2026 Financial ResultsBusiness WireRevenue of $85.4 million, growing 20.1% sequentially GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% GAAP loss of
4mo agoFLGTFulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced
5mo agoFLGTFulgent Presents Updated FID-007 Data at ASCO 2026Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the
5mo agoFLGTLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmGlobeNewswireNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. ("Fulgent" or the "Company")
5mo agoFLGTFulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual MeetingBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full
6mo agoFLGTLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmGlobeNewswireNEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. ("Fulgent" or the "Company")
6mo agoFLGTFoundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent GeneticsBusiness WireNew solution helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care FoundationOne PGx includes genes associated with the metabolism of medicines that have strong
6mo agoFLGTFulgent Genetics 1Q2026 Conference Call and WebcastFULGENT GENETICS INCEarnings Call TranscriptsGreetings. Welcome to Fulgent Genetics first quarter 2026 conference call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyon
6mo agoFLGTFulgent Reports First Quarter 2026 Financial ResultsBusiness WireReiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1
6mo agoFLGTFulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual MeetingBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its
6mo agoFLGTLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmGlobeNewswireNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. ("Fulgent" or the "Company")
6mo agoFLGTFulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
7mo agoFLGTFulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDxBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition
8mo agoFLGTLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmGlobeNewswireNEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. ("Fulgent" or the "Company")
8mo agoFLGTFULGENT GENETICS Q4 AND FULL YEAR 2025 CONFERENCE CALL AND WEBCASTFULGENT GENETICS INCEarnings Call TranscriptsGreetings. Welcome to Fulgent Genetics fourth quarter 2025 conference call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyo
8mo agoFLGTFulgent Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireRevenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4
9mo agoFLGTFulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
10mo agoFLGTFulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDxBusiness WireProposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established
1y agoFLGTFulgent to Participate in Upcoming ConferencesBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of
1y agoFLGTFulgent Reports Third Quarter 2025 Financial ResultsBusiness WireRevenue of $84.1 million, growing 17% year-over-year Raising Full Year 2025 Revenue Guidance to $325.0 million Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ($1.70) per share and Non-GAAP income
1y agoFLGTFulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 ConferenceBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary
1y agoFLGTFulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
1y agoFLGTFulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoFLGTFulgent Reports Second Quarter 2025 Financial ResultsBusiness WireCore Revenue of $81.7 million grows 16% year-over-year Raising Full Year 2025 Core Revenue Guidance to $320 million GAAP gross profit of $34.4 million, or GAAP gross margin of 42.1%; Non-GAAP gross profit of
1y agoFLGTFulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLMBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received
1y agoFLGTFulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
1y agoFLGTWolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, IncPR NewswireWolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces its investigation ...
1y agoFLGTWolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, IncGlobeNewswirePLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights
1y agoFLGTFulgent Reports First Quarter 2025 Financial ResultsBusiness WireCore Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37)
1y agoFLGTFulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
1y agoFLGTFulgent Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireFull Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable
1y agoFLGTFulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
1y agoFLGTFoundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent GeneticsBusiness WireFoundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, FoundationOne®Germline and FoundationOne®Germline More, in the
2y agoFLGTFulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoFLGTFulgent Reports Third Quarter 2024 Financial ResultsBusiness WireTotal Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent
2y agoFLGTFulgent to Participate in Upcoming ConferencesBusiness WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of
2y agoFLGTFulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been
2y agoFLGTFulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
2y agoFLGTFulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoFLGTFulgent Reports Second Quarter 2024 Financial ResultsBusiness WireTotal Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent
2y agoFLGTFulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024Business WireFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will
2y agoFLGT NEOPress release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global MarketingGlobeNewswirePRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or
2y agoFLGTFulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck CancerBusiness WireFulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ:FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead
2y agoFLGTFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual MeetingBusiness WireFulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ:FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead
2y agoFLGTMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsBusiness WireCollaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine Moffitt Cancer Center, a world-renowned cancer treatment and research center,
2y agoFLGTBrixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of PainPR NewswireBrixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic...